Cell Counting Kit-8 (CCK-8): Sensitive WST-8 Cell Viability Assay for Quantitative Cytotoxicity Measurement

Executive Summary: The Cell Counting Kit-8 (CCK-8) utilizes a water-soluble tetrazolium salt, WST-8, for colorimetric detection of viable cells via mitochondrial dehydrogenase activity (product page). This method enables direct, quantitative measurement of cell viability with improved sensitivity compared to MTT or XTT assays (Xu et al., 2025). CCK-8's workflow eliminates solubilization steps due to the aqueous nature of the formazan product. The assay is widely validated in cancer, immunometabolic, and neurodegenerative disease research (related article). Each well's absorbance quantitatively correlates with viable cell number, supporting reproducible, high-throughput applications.

Biological Rationale

Accurate measurement of cell viability is foundational in biomedical research. Cell proliferation and cytotoxicity assays inform drug screening, toxicity testing, and disease modeling. Mitochondrial dehydrogenase activity is a robust marker of viable cells, as only metabolically active cells can reduce tetrazolium salts to colored formazan derivatives. The Cell Counting Kit-8 (CCK-8) leverages this principle, enabling quantitative assessment of metabolic activity in vitro. Compared to trypan blue exclusion or manual counting, CCK-8 provides higher sensitivity, reproducibility, and suitability for automation (see comparison).

Mechanism of Action of Cell Counting Kit-8 (CCK-8)

CCK-8 relies on WST-8, a water-soluble tetrazolium salt. Live cells with active mitochondrial dehydrogenases reduce WST-8 to an orange, water-soluble formazan dye. The intensity of the formazan color, measured at 450 nm by a microplate reader, is directly proportional to the number of viable cells. No organic solvents or cell lysis are required, as the formazan remains soluble in the culture medium. The assay typically requires 1–4 hours of incubation at 37°C, with linear detection ranges specified in the product insert (Cell Counting Kit-8 (CCK-8)).

• Reaction: WST-8 + NADH/H₂ → Formazan (soluble) + NAD⁺
• Readout: Absorbance at 450 nm (reference 650 nm recommended for background correction).
• Correlation: Absorbance is linear with viable cell number in the recommended range (typically 500–100,000 cells per well for adherent cells).

Evidence & Benchmarks

• CCK-8 demonstrates higher sensitivity than MTT, XTT, and WST-1 assays, with a lower detection limit down to 500 cells/well in 96-well format (Xu et al., 2025).
• In T-ALL cell line studies, CCK-8 reliably quantifies proliferation and cytotoxicity after genetic or pharmacological intervention (Xu et al., 2025).
• Signal linearity is maintained across a broad range of cell densities and incubation times (1–4 hours), as validated in multiple cancer and metabolic models (internal review).
• CCK-8 outperforms MTT by eliminating the need for DMSO solubilization, reducing cytotoxic risk and variability (comparison article).
• Formazan product is non-toxic and permits real-time monitoring or sequential assays on the same plate (product documentation).

Applications, Limits & Misconceptions

CCK-8 is widely adopted in:

• Cancer drug screening: Quantitative measurement of cytotoxicity and proliferation in tumor cell lines (Xu et al., 2025).
• Neurodegenerative disease models: Monitoring neuronal viability under stress or pharmacological treatment (see related article).
• Immunometabolic research: Evaluating immune cell viability and metabolic shifts (CCK-8 in immunometabolic assays).
• High-throughput screening: Automated viability quantitation in 96- or 384-well formats ( This article clarifies the extended linear range and improved automation compatibility compared to prior reviews).

Common Pitfalls or Misconceptions

• Dead cells do not reduce WST-8: The assay only measures living, metabolically active cells. It cannot distinguish between apoptosis, necrosis, or quiescence.
• Compounds with reductive potential: Reducing agents (e.g., ascorbate, some antioxidants) may generate background by non-enzymatic WST-8 reduction.
• Media components interference: Phenol red and serum proteins may slightly shift baseline absorbance; always include blank and control wells.
• Cell density limits: Extremely high or low cell densities may fall outside the assay's linear range, reducing quantitation accuracy.
• Not suitable for in vivo quantification: CCK-8 is validated for in vitro cell cultures, not for tissue or whole-organism viability assessment.

Workflow Integration & Parameters

To use CCK-8, seed target cells in a 96- or 384-well plate at the desired density. After experimental treatment, add 10 μL of CCK-8 solution per 100 μL medium. Incubate at 37°C for 1–4 hours. Measure absorbance at 450 nm (reference 650 nm optional). For kinetic studies, repeated measurements can be made without cell lysis. Standard curves relating absorbance to viable cell number should be established for each cell type. The K1018 kit supports up to 1000 tests per unit and is compatible with most microplate readers (see K1018 product details).

• Recommended cell density: 5 × 10² to 1 × 10⁵ cells/well (adherent); 1 × 10³ to 2 × 10⁵ cells/well (suspension).
• Incubation: 1–4 hours at 37°C, 5% CO₂.
• Controls: Include blank (media + CCK-8) and negative (dead cell) controls for background correction.
• Downstream compatibility: The formazan product's non-toxicity allows for subsequent nucleic acid or protein extraction from the same wells.

Conclusion & Outlook

The Cell Counting Kit-8 (CCK-8) is a validated, sensitive, and convenient assay for quantifying cell viability and cytotoxicity in vitro. Its water-soluble WST-8 chemistry improves workflow simplicity and data reproducibility, outperforming traditional tetrazolium-based assays. CCK-8 continues to underpin key advances in cancer, immunometabolic, and neurodegenerative disease research, supporting high-throughput and automated applications. The method's reliability and compatibility with modern screening platforms make it a standard for quantitative cell health assessment (Xu et al., 2025).